For sometime there has been hue and cry from biopharmaceutical companies in United States regarding the extension of period of exclusivity for Biopharmaceutical drugs from 12 years to 14 years, this exclusivity will not only help these companies to protect them from Biosimilar drugs competition but will also give theses companies time to invest on development of new medicines.Yesterday there was news that a senior democrat Mr. Edward Kennedy, chairman of the Senate health committee, in United States proposed an extension of 13.5 years for these biopharmaceuticals drugs for their protection from biosimilar competition.
Under this proposal Biopharmaceuticals will be receiving nine years of protection, plus up to four-and-a-half additional years for new uses or pediatric studies.
No comments:
Post a Comment